Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies

Human malignancies are often the result of overexpressed and constitutively active receptor and non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor-driven pathways. Several tyrosine kinases (ie, EGFR, FGFR, PDGFR, VEGFR), are aberrantly activated in most common tumors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Fiona H, Putoczki, Tracy L, Stylli, Stanley S, Luwor, Rodney B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343508/
https://www.ncbi.nlm.nih.gov/pubmed/30705592
http://dx.doi.org/10.2147/OTT.S189391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343508/
https://www.ncbi.nlm.nih.gov/pubmed/30705592
http://dx.doi.org/10.2147/OTT.S189391

Ejemplares similares